ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)
University of Washington · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06174389
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–60 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 90
- US sites recruiting
- 1
- Study start
- October 1, 2023
- Record last updated
- August 29, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.
Being studied: Behavioral Weight Loss Program
Conditions: Obesity
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- BMI 30.0 - 50.0 kg/m2
- Able to attend study intervention classes and study visits/assessments
- Independently living with access to food preparation facilities
Exclusion Criteria
- Current smoker or regular use of nicotine containing products and/or cannabis
- Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use
- Known cognitive impairments or h/o stroke
- Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%))
- Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate
- Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding
- Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants
- History of bariatric surgery
- History of eating disorder
- Current participation in a formal weight loss program
- Prior or current participation in a research study involving weight loss
- Weight-reduced by >10% within past year
- Weight > 330 pounds (MRI limit)
- Allergy or intolerance to or unwillingness to consume study foods provided at visit
- MRI contraindication (e.g., implanted metal, claustrophobia)
- Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures
- Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate
Recruiting US locations
University of Washington - South Lake Union
Seattle, WA 98109
Site contact: Mary Webb · uwadaptstudy@uw.edu
Study contacts (from the official record)
- ADAPT Study · 206-616-6360 · uwadaptstudy@uw.edu
- ADAPT Study · 206-685-1532 · uwadaptstudy@uw.edu
Similar studies in Washington
All weight loss studies in Washington →- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Renton, WA + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Redmond, WA + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 2
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
AbbVie
- Location
- Renton, WA + 58 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
- Location
- Seattle, WA + 13 other US sites
- Eligibility basics
- Ages 10–18